Cytiva’s largest FlexFactory platform powers AkesoBio expansion into large scale commercial manufacturing
- Expanded manufacturing capacity will be used to meet China’s current market projections and future global needs
- Cytiva and AkesoBio are planning further builds to provide additional commercial manufacturing capacity in the years ahead.
April 26, 2021
Cytiva, a global life sciences leader, will provide another FlexFactory platform for Chinese biopharmaceutical company, AkesoBio. The 6x2000L space, their third and largest, will be used to further enhance manufacturing capacity of biologics to meet market needs in the country.
China's biopharmaceutical industry is entering a stage of rapid expansion with the market size expecting to reach more than 640 billion yuan by 20231. AkesoBio is spearheading the Chinese biologics market from research to providing commercially approved drugs.
Dr. Michelle Xia, Founder, Chairman and CEO of AkesoBio, says: “The cooperation with Cytiva lays a solid foundation for AkesoBio to become the world-leading enterprise in the R&D, production and commercialization of the next-generation affordable innovative therapeutic antibodies. Cytiva’s FlexFactory platform enables conformation with the relevant regulations of NMPA, FDA and EMA. This, along with its single use technology and modularity, helps facilitate our drug development to the maximum extent and achieve GMP production quickly.”
Olivier Loeillot, Vice President of BioProcess, Cytiva, says: “Our collaboration with AkesoBio is long standing. We have remained committed to their success since they first opened their doors eight years ago. As they have grown, we have provided the solutions, expertise, and guidance to approach each new milestone with speed and efficiency.”
Cytiva partnered with AkesoBio on their first FlexFactory platform in 2016. The project became the first biological agent production facility in Southern China to adopt flexible factory technology with a central control system. It enabled AkesoBio to quickly produce clinical drugs in the shortest production cycle, at a lower operating cost, and gave them the flexibility to quickly switch between various drug candidates. That same year, AkesoBio and Cytiva jointly established the "Southern Antibody Drug Process Development Joint Laboratory" to help AkesoBio achieve efficient process innovation. In 2019, Cytiva partnered with AkesoBio to produce a 4x2000L FlexFactory platform for the commercial production of AkesoBio research drugs.
Cytiva has over 80 FlexFactory solutions worldwide.
Know more about our FlexFactory solutions here.
About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
APAC Media Contact:
Iris Zhao
[email protected]
+86 185-0212-7884
US/CAN/EMEA Media Contact:
Tania Kimball
[email protected]
+1 978-995-3184